Symptoms and Disease Progression
At a Glance
Gyrate atrophy often starts in childhood with night blindness and progresses to nearsightedness and narrowing side vision. Regular eye and metabolic follow-up can detect cataracts and macular problems early, while sudden central vision changes require urgent evaluation.
Understanding the progression of Gyrate Atrophy helps families prepare for changes and recognize when symptoms require immediate medical attention. While the condition primarily affects the eyes, it is a whole-body metabolic disorder that can sometimes cause symptoms outside of vision.
The Timeline of Vision Changes
In most cases, the first signs of Gyrate Atrophy appear in childhood, often between the ages of 3 and 10 [1][2]. The progression typically follows a specific pattern, though the speed of change varies from person to person.
- Night Blindness (Nyctalopia): This is usually the earliest symptom. You or your child may notice difficulty seeing in dim light, such as at a movie theater or outdoors at dusk [3].
- Myopia (Nearsightedness): High degrees of nearsightedness are common and often develop or worsen significantly during the second decade of life [4][1].
- Peripheral Vision Loss: As the areas of damage (atrophy) at the edges of the retina grow, the “side vision” begins to constrict. This is often described as “tunnel vision” and typically becomes more noticeable in the teen years or early adulthood [5].
- Central Vision Changes: For many years, the center of the vision may remain clear. However, in later stages or due to specific complications, central vision can become blurred or lost [3].
Ocular Complications
Beyond the gradual loss of peripheral vision, several specific complications can occur. These are often treatable, making regular monitoring essential.
- Early-Onset Cataracts: People with Gyrate Atrophy often develop presenile cataracts (clouding of the eye’s lens) much earlier than the general population. In one study group, nearly two-thirds of patients developed cataracts, often requiring surgery in their 20s or 30s [4][6]. Keep in mind these statistics describe a specific cohort, and individual outcomes vary.
- Cystoid Macular Edema (CME): This is a buildup of fluid in the macula (the center of the retina). It can cause central vision to feel blurry or “swollen” [1][7].
- Foveoschisis: This is a condition where the layers of the central retina begin to split. It has been seen in more than half of eyes in some large studies and can lead to a decrease in central sharpness [4][8].
- Macular Neovascularization (MNV): This is a serious but rare complication where abnormal blood vessels grow under the retina. These vessels can leak or bleed, leading to rapid vision changes [9].
Warning Signs: When to Seek Urgent Care
While most vision loss in Gyrate Atrophy is slow, certain symptoms are “red flags” that require a same-day appointment with an ophthalmologist. If your eye specialist is unavailable, seek guidance from an emergency department.
| Symptom | Potential Cause |
|---|---|
| Sudden loss of central vision | Bleeding or fluid from Macular Neovascularization [9] |
| Distorted vision (straight lines look wavy) | Fluid buildup or new blood vessel growth [10] |
| A new “blind spot” in the center of vision | Macular damage or hemorrhage [9] |
| A “curtain” or “shadow” over the vision | Retinal detachment (a rare but serious risk) [11] |
| New flashes of light or a sudden shower of floaters | Retinal tear or detachment |
Symptoms Beyond the Eyes
Because the enzyme deficiency affects the whole body, some individuals experience extraocular (non-eye) symptoms. These occur because the metabolic imbalance can affect muscle and brain function.
- Muscle and Growth: Some patients show a trend toward reduced fat-free mass (muscle mass) or muscle weakness (hypotonia) [6][12].
- Developmental Delay: A subset of patients may experience mild developmental delays or learning difficulties [6].
- Cerebral Creatine Deficiency: High levels of ornithine can block the body’s ability to produce creatine, a vital energy source for the brain. In one targeted small study, 75% of patients tested with specialized imaging (MR spectroscopy) showed low brain creatine levels [2]. In these research settings, it is often treated with oral creatine supplements to support brain health [2]. Note that this represents findings from selected small studies, not a universal prevalence, and supplementation is specialist-directed.
Regular follow-ups with both an eye specialist and a metabolic doctor are necessary to track these symptoms and adjust treatments as the condition progresses.
Common questions in this guide
What symptoms usually appear first with gyrate atrophy?
Can gyrate atrophy affect central vision?
Which vision changes need urgent attention?
Does gyrate atrophy cause symptoms outside the eyes?
How are cataracts and other eye complications monitored?
Could a person with gyrate atrophy have low brain creatine?
Get notified when new evidence is published on Gyrate atrophy of choroid and retina.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
A cohort study of 19 patients with gyrate atrophy of the choroid and retina (GACR).
Balfoort BM, Van Den Broeck F, Brands MM, et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2024; (262(11)):3589-3596 doi:10.1007/s00417-024-06540-8.
PMID: 38847892 - 2
Novel Insights Into Gyrate Atrophy of the Choroid and Retina (GACR): A Cohort Study.
Balfoort BM, Van den Broeck F, Boon CJF, et al.
Journal of inherited metabolic disease 2025; (48(1)):e12842 doi:10.1002/jimd.12842.
PMID: 39761806 - 3
Gyrate Atrophy of the Choroid and Retina: A Review.
Elnahry AG, Elnahry GA
European journal of ophthalmology 2022; (32(3)):1314-1323 doi:10.1177/11206721211067333.
PMID: 34894815 - 4
Widefield Retinal Imaging in Gyrate Atrophy: Correlation of Structural, Biochemical, and Functional Characteristics.
Padhy SK, Parameswarappa DC, Sharma S, et al.
Ophthalmology. Retina 2025; (9(4)):392-401 doi:10.1016/j.oret.2024.10.016.
PMID: 39447872 - 5
Inborn Errors of Metabolism: Gyrate Atrophy.
Hartung KJ, Tsang SH, Sharma T, Diaconita V
Advances in experimental medicine and biology 2025; (1467()):197-200 doi:10.1007/978-3-031-72230-1_37.
PMID: 40736839 - 6
Clinical, biochemical and molecular analysis in a cohort of individuals with gyrate atrophy.
Palmer E, Stepien KM, Campbell C, et al.
Orphanet journal of rare diseases 2023; (18(1)):265 doi:10.1186/s13023-023-02840-0.
PMID: 37667371 - 7
Treatment of Intraretinal Cystic Spaces Associated With Gyrate Atrophy of the Choroid and Retina With Intravitreal Bevacizumab.
Elnahry AG, Aboulfotouh MR, Nassar GA
Journal of pediatric ophthalmology and strabismus 2020; (57(6)):400-406 doi:10.3928/01913913-20200813-01.
PMID: 33211898 - 8
Ultrawide field fluorescein angiogram in a family with gyrate atrophy and foveoschisis.
Tripathy K, Chawla R, Sharma YR, Gogia V
Oman journal of ophthalmology 2016; (9(2)):104-6 doi:10.4103/0974-620X.184529.
PMID: 27433038 - 9
Macular neovascularization in patients with Gyrate atrophy.
Bierbrier J, Ahmed Y, Ventresca M, et al.
Ophthalmic genetics 2026; 1-7 doi:10.1080/13816810.2026.2671407.
PMID: 42220020 - 10
Intravitreal ranibizumab for choroidal neovascularization secondary to gyrate atrophy in a young patient: a multimodal imaging analysis.
Chatziralli I, Theodossiadis G, Emfietzoglou I, Theodossiadis P
European journal of ophthalmology 2015; (25(6)):e119-22.
PMID: 26419008 - 11
A novel c.980C>G variant in OAT results in identifiable gyrate atrophy phenotype associated with retinal detachment in a young female.
Magliyah M, Alsalamah AK, AlOtaibi M, Nowilaty SR
Ophthalmic genetics 2021; (42(2)):204-208 doi:10.1080/13816810.2020.1843185.
PMID: 33243052 - 12
First report of c.425-1G>A mutation in ornithine aminotransferase gene causing gyrate atrophy of the choroid and retina with hyperornithinemia.
Jalali H, Najafi M, Khoshaeen A, et al.
European journal of ophthalmology 2021; (31(5)):NP23-NP26 doi:10.1177/1120672120921734.
PMID: 32418451
This page describes gyrate atrophy symptoms and progression for informational purposes only and does not replace medical advice. Contact an ophthalmologist or metabolic specialist promptly about sudden vision changes or concerns about your specific care.